Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	621,691 shs	N/A
GOVX GeoVax Labs	$1.03 +1.0%	$1.00	$0.73 ▼ $11.18	$15.65M	3.47	518,512 shs	378,850 shs
MGX Metagenomi	$1.77 +3.8%	$1.56	$1.23 ▼ $6.90	$65.98M	-0.65	791,924 shs	295,110 shs
PYRGF PyroGenesis Canada	$0.39 -2.0%	$0.33	$0.30 ▼ $0.80	$71.93M	0.79	11,138 shs	8,995 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	+7.25%	+60.87%
GOVX GeoVax Labs	0.00%	+3.55%	+3.55%	-30.74%	-42.53%
MGX Metagenomi	0.00%	+4.34%	+4.99%	-9.12%	-73.51%
PYRGF PyroGenesis Canada	0.00%	+20.59%	+21.64%	-8.77%	-11.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	3.1642 of 5 stars	3.6	4.0	0.0	0.0	2.0	1.7	1.3
MGX Metagenomi	2.2678 of 5 stars	3.5	3.0	0.0	0.0	2.6	0.0	0.0
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
GOVX GeoVax Labs	3.29	Buy	$11.10	977.67% Upside
MGX Metagenomi	3.00	Buy	$13.00	636.54% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GOVX, PYRGF, ACHL, and MGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/3/2025	MGX Metagenomi	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $7.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/18/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
GOVX GeoVax Labs	$5.59M	2.80	N/A	N/A	$3.24 per share	0.32
MGX Metagenomi	$45.26M	1.46	N/A	N/A	N/A	∞
PYRGF PyroGenesis Canada	$9.14M	7.87	N/A	N/A	($0.01) per share	-38.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	8/12/2025 (Estimated)
GOVX GeoVax Labs	-$25.97M	-$3.65	N/A	N/A	N/A	N/A	-809.87%	-349.34%	8/5/2025 (Estimated)
MGX Metagenomi	-$68.25M	-$2.11	N/A	N/A	N/A	-134.27%	-43.23%	-18.86%	8/13/2025 (Estimated)
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest GOVX, PYRGF, ACHL, and MGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million
3/17/2025	Q4 2024	MGX Metagenomi	-$0.62	-$0.63	-$0.01	-$0.63	$13.18 million	$9.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
GOVX GeoVax Labs	N/A	4.17	4.17
MGX Metagenomi	N/A	6.18	6.18
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
GOVX GeoVax Labs	6.09%
MGX Metagenomi	N/A
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
GOVX GeoVax Labs	1.20%
MGX Metagenomi	N/A
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
GOVX GeoVax Labs	10	15.19 million	8.90 million	Not Optionable
MGX Metagenomi	236	37.38 million	N/A	N/A
PYRGF PyroGenesis Canada	90	186.69 million	96.34 million	No Data

GOVX, PYRGF, ACHL, and MGX Headlines

Recent News About These Companies

PyroGenesis Canada (NASDAQ:PYRGF) Trading Up 1.1% - What's Next?

June 1 at 2:58 AM | marketbeat.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Trading Down 0.2% - Should You Sell?

May 11, 2025 | marketbeat.com

PyroGenesis Schedules First Quarter 2025 Financial Results and Business Update Conference Call

May 9, 2025 | globenewswire.com

PyroGenesis Announces Closing of Non-Brokered Private Placement of up to $5,750,000

May 5, 2025 | globenewswire.com

P. Peter Pascali Updates Early Warning Report

April 10, 2025 | globenewswire.com

PyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call Transcript

April 1, 2025 | seekingalpha.com

PyroGenesis Announces Fourth Quarter and Full Year 2024 Results

March 31, 2025 | globenewswire.com

PyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference Call

March 26, 2025 | globenewswire.com

PyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | finanznachrichten.de

PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | globenewswire.com

HPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica Production

March 12, 2025 | markets.businessinsider.com

PyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)

March 11, 2025 | globenewswire.com

PyroGenesis Provides Response to Impact of U.S. Tariffs

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX, PYRGF, ACHL, and MGX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)

As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

GeoVax Labs NASDAQ:GOVX

$1.03 +0.01 (+0.98%)

As of 03:57 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Metagenomi NASDAQ:MGX

$1.76 +0.07 (+3.82%)

Closing price 03:59 PM Eastern

Extended Trading

$1.76 0.00 (0.00%)

As of 04:15 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

PyroGenesis Canada NASDAQ:PYRGF

$0.39 -0.01 (-1.96%)

As of 02:50 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time